Literature DB >> 10403176

Serum and tissue thyroglobulin measurement: clinical applications in thyroid disease.

F Pacini1, A Pinchera.   

Abstract

Since the first demonstration by Van Herle et al. that thyroglobuling (Tg), the main iodo-protein of the thyroid gland, was detectable in the circulation of normal subjects by using specific radioimmunoassay, an impressive amount of papers has been produced, describing several clinical applications of Tg measurements. Now, measurement of Tg is the mainstay in the post-surgical follow-up of differentiated thyroid cancer and an integral part in the diagnostic evaluation of patients with benign thyroid diseases. In this article we will review the most relevant clinical application of Tg measurements in the blood and in other biological material, including: a) serum Tg in perinatal age and congenital hypothyroidism; b) serum Tg measurements in thyrotoxicosis factitia and in other thyrotoxic conditions associated with low iodine uptake; c) differential diagnosis of thyroid and parathyroid cysts; and d) clinical relevance of Tg measurement in thyroid cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10403176     DOI: 10.1016/s0300-9084(99)80096-0

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  8 in total

1.  Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment.

Authors:  Leonardo Pace; Michele Klain; Carmine Albanese; Barbara Salvatore; Giovanni Storto; Andrea Soricelli; Marco Salvatore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-10-05       Impact factor: 9.236

2.  Role of the asialoglycoprotein receptor in binding and entry of hepatitis C virus structural proteins in cultured human hepatocytes.

Authors:  Bertrand Saunier; Miriam Triyatni; Luca Ulianich; Padma Maruvada; Paul Yen; Leonard D Kohn
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

3.  Failure to use measurement of megalin secretory components complexed with serum thyroglobulin as a tool to identify metastases after surgery in papillary thyroid cancer.

Authors:  S Lisi; F Menconi; M A Altea; L Agate; E Molinaro; M G Castagna; D Taddei; L Grasso; A Pinchera; R Elisei; M Marinò
Journal:  J Endocrinol Invest       Date:  2004 Jul-Aug       Impact factor: 4.256

4.  Impact of Thyroid Tissue Status on the Cut-Off Value of Lymph Node Fine-Needle Aspiration Thyroglobulin Measurements in Papillary Thyroid Cancer.

Authors:  L Zhai; W Jiang; Y Zang; Y Gao; D Jiang; Q Tian; C Zhao
Journal:  Br J Biomed Sci       Date:  2022-01-12       Impact factor: 2.432

Review 5.  Radioiodine therapy for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases.

Authors:  Chao Ma; Anren Kuang; Jiawei Xie
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21

6.  Nanotechnology for early cancer detection.

Authors:  Young-Eun Choi; Ju-Won Kwak; Joon Won Park
Journal:  Sensors (Basel)       Date:  2010-01-06       Impact factor: 3.576

7.  Thyroid heterogeneity, as indicated by the CV of ultrasonographic intensities, correlates with anti-thyroid peroxidase antibodies in euthyroid Hashimoto's thyroiditis.

Authors:  Yosuke Wakita; Toshiki Nagasaki; Yuki Nagata; Yasuo Imanishi; Shinsuke Yamada; Koichiro Yoda; Masanori Emoto; Eiji Ishimura; Masaaki Inaba
Journal:  Thyroid Res       Date:  2013-03-23

8.  Lung Recurrence of Papillary Thyroid Cancer Diagnosed With Antithyroglobulin Antibodies After 10 Years From Initial Treatment.

Authors:  David Viola; Laura Agate; Eleonora Molinaro; Valeria Bottici; Loredana Lorusso; Francesco Latrofa; Liborio Torregrossa; Laura Boldrini; Teresa Ramone; Paolo Vitti; Rossella Elisei
Journal:  Front Endocrinol (Lausanne)       Date:  2018-10-09       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.